I agree that this site is using cookies. You can find further informations here.
X
Düll, Johannes
19  results:
Search for persons X
?
1

Th17.1 cell driven sarcoidosis-like inflammation after anti..:

Leipold, Alexander M. ; Werner, Rudolf A. ; Düll, Johannes...
Leukemia.  37 (2023)  3 - p. 650-658 , 2023
Link: https://doi.org/10.1038/..
 
?
2

Targeting CD19 in diffuse large B‐cell lymphoma: An expert ..:

Bailly, Sarah ; Cartron, Guillaume ; Chaganti, Sridhar...
Hematological Oncology.  40 (2022)  4 - p. 505-517 , 2022
Link: https://doi.org/10.1002/..
 
?
3

CD52 and OXPHOS—potential targets in ibrutinib-treated mant..:

Fuhr, Viktoria ; Heidenreich, Shanice ; Srivastava, Mugdha...
Cell Death Discovery.  8 (2022)  1 - p. , 2022
Link: https://doi.org/10.1038/..
 
?
4

The use of tafasitamab in diffuse large B-cell lymphoma:

Düll, Johannes ; Topp, Max ; Salles, Gilles
Therapeutic Advances in Hematology.  12 (2021)  - p. 204062072110274 , 2021
Link: https://doi.org/10.1177/..
 
?
5

Obinutuzumab and venetoclax induced complete remission in a..:

Zhou, Xiang ; Steinhardt, Maximilian Johannes ; Düll, Johannes...
European Journal of Haematology.  104 (2020)  4 - p. 352-355 , 2020
Link: https://doi.org/10.1111/..
 
?
6

Trade-off designs and comparative exergy evaluation of soli..:

Wang, Ligang ; Düll, Johannes ; Maréchal, François.
International Journal of Hydrogen Energy.  44 (2019)  19 - p. 9529-9543 , 2019
Link: https://doi.org/10.1016/..
 
?
7

Outcome of patients with relapsed/refractory acute lymphobl..:

Jabbour, Elias ; Düll, Johannes ; Yilmaz, Musa...
American Journal of Hematology.  93 (2017)  3 - p. 371-374 , 2017
Link: https://doi.org/10.1002/..
 
?
8

Th17.1 cell driven sarcoidosis-like inflammation after anti..:

Leipold, Alexander M ; Werner, Rudolf A ; Düll, Johannes...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9888347/.  , 2023
Link: http://www.ncbi.nlm.nih...
 
?
9

CD52 and OXPHOS-potential targets in ibrutinib-treated mant..:

Fuhr, Viktoria ; Heidenreich, Shanice ; Srivastava, Mugdha...
https://opus.bibliothek.uni-wuerzburg.de/frontdoor/index/index/docId/30081.  , 2022
Link: https://opus.bibliothek...
 
?
10

Targeting CD19 in diffuse large B-cell lymphoma: An expert ..:

Bailly, Sarah ; Cartron, Guillaume ; Chaganti, Sridhar...
boreal:263829.  , 2022
Link: http://hdl.handle.net/20..
 
?
11

Targeting CD19 in diffuse large B-cell lymphoma : An expert..:

Bailly, Sarah ; Cartron, Guillaume ; Chaganti, Sridhar...
Hematological Oncology.  , 2022
Link: https://ddd.uab.cat/reco..
 
?
12

Targeting CD19 in diffuse large B-cell lymphoma: An expert ..:

Bailly, Sarah ; Cartron, Guillaume ; Chaganti, Sridhar...
boreal:263829.  , 2022
Link: http://hdl.handle.net/20..
 
?
13

CD52 and OXPHOS—potential targets in ibrutinib-treated mant..:

Fuhr, Viktoria ; Heidenreich, Shanice ; Srivastava, Mugdha...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9805448/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
?
14

The use of tafasitamab in diffuse large B-cell lymphoma:

Düll, Johannes ; Topp, Max ; Salles, Gilles
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264734/.  , 2021
Link: http://www.ncbi.nlm.nih...
 
?
15

Polatuzumab vedotin as a salvage and bridging treatment in ..:

Liebers, Nora ; Düll, Johannes ; Fitzgerald, Donnacha...
http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/62915.  , 2021
Link: http://publikationen.ub...
 
1-15